Table I. Characteristics of CLL Patients at the Time of Hodgkin Lymphoma Diagnosis.
| Characteristic | N (%) | |
|---|---|---|
| Number of patients | 26 | |
| Median age, years (range) | 67 (45–88) | |
| Male | 21 (81) | |
| Median WBC, ×109/L (range) | 7.8 (1.3–87.3) | |
| Median HB, g dL−1(range) | 11 (7.2–13) | |
| Median PLT, ×109/L (range) | 220.5 (53–627) | |
| Median LDH, U L−1(range) | 249 (133–658) | |
| Median creatinine, mg dL−1 (range) | 1 (0.6–2.1) | |
| Median albumin, g dL−1(range) | 3.5 (2.6–4.2) | |
| Ann Arbor stage | I | 0 |
| II | 10 (38) | |
| III | 3 (11) | |
| IV | 11 (42) | |
| Undetermined | 2 (8) | |
| Epstein–Barr virus statusa | Positive | 6 (67) |
| Negative | 3 (33) | |
| Not done | 17 | |
| Prior CLL therapy before HL diagnosis | No | 9 (35) |
| Yes | 17 (65) | |
| Purine analog containing regimen | 13 (50) | |
| Therapy administered for of HL | ABVD | 16 (61) |
| MOPP/ABV hybrid | 3 (11) | |
| BCVPP | 2 (8) | |
| CVPP | 1 (4) | |
| VP | 1 (4) | |
| Unknown | 3 (11) |
a
Performed clinically on select patients.
Abbreviations used: WBC; white cell count; HB: hemoglobin; PLT; platelet; LDH; lactate dehydrogenase; ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine; MOPP/ABV hybrid: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) followed by doxorubicin, bleomycin and vinblastine (ABV); BCVPP: carmustine, cyclophosphamide, vinblastine, pro-carbazine, and prednisone; CVPP: chlorambucil, vincristine, procarbazine and prednisone; VP: vinblastine and prednisone.